IDH1 and glioma: A study suggests that targeting pyrimidine metabolism reprogramming in cancer stem cells and lower expression of pyrimidine metabolism indicates a better prognosis of glioblastoma (35), and pharmacologic inhibition of glutathione metabolism could be valuable for patients with IDH1-mutated glioma (36).